JPWO2020209285A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020209285A5 JPWO2020209285A5 JP2021513667A JP2021513667A JPWO2020209285A5 JP WO2020209285 A5 JPWO2020209285 A5 JP WO2020209285A5 JP 2021513667 A JP2021513667 A JP 2021513667A JP 2021513667 A JP2021513667 A JP 2021513667A JP WO2020209285 A5 JPWO2020209285 A5 JP WO2020209285A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- pharmaceutical composition
- acid strand
- composition according
- analogue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025081949A JP2025118886A (ja) | 2019-04-08 | 2025-05-15 | 筋疾患治療用医薬組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019073832 | 2019-04-08 | ||
| JP2019073832 | 2019-04-08 | ||
| PCT/JP2020/015818 WO2020209285A1 (ja) | 2019-04-08 | 2020-04-08 | 筋疾患治療用医薬組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025081949A Division JP2025118886A (ja) | 2019-04-08 | 2025-05-15 | 筋疾患治療用医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2020209285A1 JPWO2020209285A1 (enExample) | 2020-10-15 |
| JPWO2020209285A5 true JPWO2020209285A5 (enExample) | 2023-04-17 |
| JP7687682B2 JP7687682B2 (ja) | 2025-06-03 |
Family
ID=72750688
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021513667A Active JP7687682B2 (ja) | 2019-04-08 | 2020-04-08 | 筋疾患治療用医薬組成物 |
| JP2025081949A Pending JP2025118886A (ja) | 2019-04-08 | 2025-05-15 | 筋疾患治療用医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025081949A Pending JP2025118886A (ja) | 2019-04-08 | 2025-05-15 | 筋疾患治療用医薬組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220175817A1 (enExample) |
| EP (1) | EP3954395A4 (enExample) |
| JP (2) | JP7687682B2 (enExample) |
| CN (1) | CN113677374A (enExample) |
| WO (1) | WO2020209285A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020028832A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| AU2019316103B2 (en) | 2018-08-02 | 2026-02-19 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| EP4259798A1 (en) * | 2020-12-11 | 2023-10-18 | Eisai R&D Management Co., Ltd. | Poly-morpholino oligonucleotide gapmers |
| EP4349986A4 (en) * | 2021-05-25 | 2025-11-19 | Univ Nat Corp Tokyo Medical & Dental | HETERONUCLEIC ACID WITH A CONTENT OF ?????? OR ???? |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| WO2023022229A1 (ja) * | 2021-08-19 | 2023-02-23 | 国立大学法人東京医科歯科大学 | モルホリノ核酸を含む修飾ヘテロ核酸 |
| US20240390508A1 (en) | 2021-08-21 | 2024-11-28 | Takeda Pharmaceutical Company Limited | Human transferrin receptor binding peptide-drug conjugate |
| CA3229962A1 (en) | 2021-08-24 | 2023-03-02 | Peptidream Inc. | Human transferrin receptor-binding antibody-peptide conjugate |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| GB202215614D0 (en) | 2022-10-21 | 2022-12-07 | Proqr Therapeutics Ii Bv | Heteroduplex rna editing oligonucleotide complexes |
| JP2025536808A (ja) | 2022-11-24 | 2025-11-07 | プロキューアール・セラピューティクス・セカンド・ベスローテン・フェンノートシャップ | 遺伝性ｈｆｅヘモクロマトーシスの治療のためのアンチセンスオリゴヌクレオチド |
| GB202218090D0 (en) | 2022-12-01 | 2023-01-18 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency |
| JP2025540146A (ja) | 2022-12-09 | 2025-12-11 | プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ | 心血管疾患の治療のためのアンチセンスオリゴヌクレオチド |
| GB202300865D0 (en) | 2023-01-20 | 2023-03-08 | Proqr Therapeutics Ii Bv | Delivery of oligonucleotides |
| EP4669753A1 (en) | 2023-02-20 | 2025-12-31 | ProQR Therapeutics II B.V. | Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease |
| WO2024206175A1 (en) | 2023-03-24 | 2024-10-03 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of neurological disorders |
| GB202304363D0 (en) | 2023-03-24 | 2023-05-10 | Proqr Therapeutics Ii Bv | Chemically modified antisense oligonucleotides for use in RNA editing |
| CN121002181A (zh) | 2023-03-27 | 2025-11-21 | ProQR治疗上市公司Ⅱ | 用于治疗肝脏疾病的反义寡核苷酸 |
| TW202516003A (zh) | 2023-06-16 | 2025-04-16 | 荷蘭商Ｐｒｏｑｒ治療上市公司Ｉｉ | 用於治療神經退化性疾病之反義寡核苷酸 |
| WO2025051946A1 (en) | 2023-09-07 | 2025-03-13 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of metabolic disorders |
| WO2025104239A1 (en) | 2023-11-16 | 2025-05-22 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of classic galactosemia |
| WO2025132708A1 (en) | 2023-12-20 | 2025-06-26 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of huntington's disease |
| GB202404661D0 (en) | 2024-04-02 | 2024-05-15 | Proqr Therapeutics Ii Bv | Antisense oligoncleotides for the treatment of liver disease |
| GB202405143D0 (en) | 2024-04-11 | 2024-05-29 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of poly-q disease |
| WO2025224230A1 (en) | 2024-04-25 | 2025-10-30 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of fatty liver disease |
| GB202410081D0 (en) | 2024-07-11 | 2024-08-28 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of cardiovascular disease |
| WO2026022136A1 (en) | 2024-07-23 | 2026-01-29 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of metabolic disorders |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2564616C (en) * | 2004-04-20 | 2016-08-30 | Nastech Pharmaceutical Company Inc. | Methods and compositions for enhancing delivery of double-stranded rna or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells |
| CA3044969A1 (en) | 2006-05-05 | 2007-12-21 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating gene expression |
| CA2666191C (en) | 2006-10-09 | 2017-07-11 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of pcsk9 |
| DK2092065T4 (da) | 2006-10-18 | 2019-10-21 | Ionis Pharmaceuticals Inc | Antisense-forbindelser |
| EP2762567B1 (en) * | 2008-10-24 | 2016-07-13 | Sarepta Therapeutics, Inc. | Multiple exon skipping compositions for DMD |
| ES2593836T3 (es) * | 2009-04-24 | 2016-12-13 | Biomarin Technologies B.V. | Oligonucleótido que comprende una inosina para tratar la DMD |
| WO2013089283A1 (en) * | 2011-12-16 | 2013-06-20 | National University Corporation Tokyo Medical And Dental University | Chimeric double-stranded nucleic acid |
| CN105008533A (zh) * | 2013-03-01 | 2015-10-28 | 国立大学法人东京医科齿科大学 | 嵌合单链反义多核苷酸和双链反义试剂 |
| KR20230074606A (ko) * | 2013-03-14 | 2023-05-30 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 근육 이영양증의 치료를 위한 엑손 스키핑 조성물 |
| AU2014272526A1 (en) * | 2013-05-30 | 2015-12-10 | National University Corporation Tokyo Medical And Dental University | Double-stranded agents for delivering therapeutic oligonucleotides |
| CA2915443A1 (en) * | 2013-06-16 | 2014-12-24 | National University Corporation Tokyo Medical And Dental University | Double-stranded antisense nucleic acid with exon-skipping effect |
| CA2932624C (en) * | 2013-12-09 | 2023-03-28 | Texas Heart Institute | Treating cardiac conditions using shrna or sirna targeting salvador (sav1) |
| US11116843B2 (en) * | 2015-09-25 | 2021-09-14 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
| WO2017062835A2 (en) * | 2015-10-09 | 2017-04-13 | Sarepta Therapeutics, Inc. | Compositions and methods for treating duchenne muscular dystrophy and related disorders |
| EP3366773A4 (en) * | 2015-10-23 | 2019-06-12 | Rena Therapeutics Inc. | NUCLEIC COMPLEX |
| JP7043078B2 (ja) * | 2016-09-23 | 2022-03-29 | 国立大学法人 東京医科歯科大学 | 血液脳関門通過型ヘテロ２本鎖核酸 |
| JP7129702B2 (ja) * | 2016-09-29 | 2022-09-02 | 国立大学法人 東京医科歯科大学 | オーバーハングを有する二本鎖核酸複合体 |
| EP3571300A1 (en) * | 2017-01-19 | 2019-11-27 | ProQR Therapeutics II B.V. | Oligonucleotide complexes for use in rna editing |
| GB201711809D0 (en) * | 2017-07-21 | 2017-09-06 | Governors Of The Univ Of Alberta | Antisense oligonucleotide |
| EA201991450A1 (ru) * | 2017-09-22 | 2019-12-30 | Сарепта Терапьютикс, Инк. | Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии |
| EP3687577A1 (en) * | 2017-09-28 | 2020-08-05 | Sarepta Therapeutics, Inc. | Combination therapies for treating muscular dystrophy |
| JP2019073832A (ja) | 2017-10-18 | 2019-05-16 | 合同会社型壱 | 帽子の製造方法、及びこれに用いる型 |
-
2020
- 2020-04-08 WO PCT/JP2020/015818 patent/WO2020209285A1/ja not_active Ceased
- 2020-04-08 JP JP2021513667A patent/JP7687682B2/ja active Active
- 2020-04-08 CN CN202080025994.6A patent/CN113677374A/zh active Pending
- 2020-04-08 EP EP20788494.1A patent/EP3954395A4/en active Pending
- 2020-04-08 US US17/602,035 patent/US20220175817A1/en active Pending
-
2025
- 2025-05-15 JP JP2025081949A patent/JP2025118886A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020209285A5 (enExample) | ||
| JP2023123491A5 (enExample) | ||
| CN114681621B (zh) | 肽寡核苷酸缀合物 | |
| JP5209204B2 (ja) | ポリマーオリゴヌクレオチドプロドラッグ | |
| JPWO2023026994A5 (enExample) | ||
| JP2010533171A5 (enExample) | ||
| JP7269968B2 (ja) | ペプチド担体上の多重オリゴヌクレオチド部分 | |
| US20200385735A1 (en) | Modified gapmer oligonucleotides and methods of use | |
| JP2018530560A5 (enExample) | ||
| JP2021500016A5 (enExample) | ||
| JPWO2023022229A5 (enExample) | ||
| TW202019442A (zh) | 用於反義遞送之三聚合肽 | |
| CN114615998A (zh) | 缀合物及其用途 | |
| US20040072743A1 (en) | Pharmaceutical composition of modified pna molecules | |
| WO2015172889A1 (de) | Peptid-nukleinsäuren-monomere und -oligomere | |
| JP2013537404A5 (enExample) | ||
| JPWO2021187392A5 (enExample) | ||
| AU2021226089A1 (en) | Antisense nucleic acid inducing skipping of exon 51 | |
| EP3947677A1 (en) | Oligonucleotides for modulating atxn2 expression | |
| JP2001524942A (ja) | アンチセンス・オリゴヌクレオチド薬物 | |
| Tamamura et al. | Synthesis and evaluation of bifunctional anti-HIV agents based on specific CXCR4 antagonists-AZT conjugation | |
| JP2004538272A5 (enExample) | ||
| KR20190123351A (ko) | 개질된 올리고뉴클레오티드 및 이의 치료 용도 | |
| JP5865347B2 (ja) | ポリアミド化合物及びミトコンドリア遺伝子疾患治療用医薬組成物 | |
| WO2017043639A1 (ja) | キメラデコイ |